Growth Metrics

Arrowhead Pharmaceuticals (ARWR) Non-Current Debt (2016 - 2025)

Arrowhead Pharmaceuticals' Non-Current Debt history spans 8 years, with the latest figure at $163.1 million for Q4 2025.

  • For Q4 2025, Non-Current Debt fell 60.0% year-over-year to $163.1 million; the TTM value through Dec 2025 reached $163.1 million, down 60.0%, while the annual FY2025 figure was $214.9 million, 45.35% down from the prior year.
  • Non-Current Debt reached $163.1 million in Q4 2025 per ARWR's latest filing, down from $214.9 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $407.8 million in Q4 2024 to a low of $163.1 million in Q4 2025.